凋亡调节蛋白survivin在弥漫大B细胞淋巴瘤中的研究进展

弥漫大B细胞淋巴瘤（diffuse large B-cell lymphoma，DLBCL）是最常见的非霍奇金淋巴瘤，它具有明显的生物异质性。survivin是调亡抑制蛋白家族的独特成员，它在各种肿瘤中包括某些类型的淋巴瘤中过度表达，新近发现凋亡抑制蛋白survivin在DLBCL的发生发展中起着关键的作用，其具有抑制细胞凋亡和增强细胞增生的双重调节功能。许多研究还表明，survivin可作为DLBCL的一个独立的临床预后指标，与国际预后指数（International Prognostic Index，IPI）结合可在早期筛选出常规治疗预后不良的病例，有助于指导治疗、改善预后。survivin选择性表达于肿瘤组织，为治疗肿瘤提供了理想的靶点，调节survivin的表达和功能可能成为治疗DLBCL的一个新途径。本文就survivin的作用机制，在DLBCL中的表达及其在DLBCL诊断治疗中的价值等研究进展和前景进行了综述。

Progress of Study on Survivin in Diffuse Large B-cell Lymphoma Review

Diffuse large B-cell lymphoma(DLBCL) is the most common type of non-Hodgkin's lymphoma(NHL),which is also a significantly heterogeneous disease.Survivin,a unique member of the inhibitor of apoptosis(IAP)family,is overexpressed in various cancers,including some types of lymphoma.It is found that inhibitor of apoptosis protein,survivin,plays an important role in the development and progression of DLBCL.Survivin is able to inhibit the cell apoptosis,and enhances the cell proliferation.Many studies showed that survivin may be considered as an independent unfavorable prognostic index of DLBCL.The poor prognostic cases early are screened in combination of survivin expression with International Prognostic Index(IPI),and improve the outcome of DLBCL.Survivin selectively expressed in tumor tissue,which provide an ideal target for tumor therapy.Modulation of survivin expression or function may provide a novel approach for experimental therapy in patients with DLBCL.In this review,the progress of study on mechanism of survivin protein,the survivin expression in DLBCL,its significancy in diagnosis and therapy of DLBCL,and the prospective trend were summarized.